PF-06651600 for the Treatment of Alopecia Areata

Status:	Recruiting
Conditions:	Dermatology, Dermatology, Hair Loss
Therapuetic Areas:	Dermatology / Plastic Surgery
Healthy:	No
Age Range:	12 - Any
Updated:	3/28/2019
Start Date:	December 3, 2018
End Date:	March 28, 2021
Contact:	Pfizer CT.gov Call Center
Email:	ClinicalTrials.gov_Inquiries@pfizer.com
Phone:	1-800-718-1021

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an
investigational study drug (called PF-06651600) in adults and adolescents (12 years and
older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that
some patients entering the study will not receive active study drug but will receive tablets
with no active ingredients (a placebo). This is a dose-ranging study, investigating 5
different dosing regimens. It will be double-blinded, meaning that the sponsor, the study
doctors, the staff, and the patients will not know whether a patient is on active study drug
(or the dose) or placebo.

Inclusion Criteria:

- Clinical diagnosis of alopecia areata with no other cause of hair loss

- ≥50% hair loss of the scalp, including alopecia totalis and alopecia universalis,
without evidence of terminal hair regrowth within 6 months

- Current episode of hair loss ≤10 years

Exclusion Criteria:

- Other types of alopecia or other diseases that can cause hair loss

- Other scalp diseases that could interfere with assessment of hair loss/regrowth

- Subjects with shaved heads must not enter the study until hair has grown back & is
considered stable by the investigator

- Any previous use of any Janus kinase (JAK) inhibitor

We found this trial at

sites

Vital Prospects Clinical Research Institute, P.C.

6565 S. Yale Ave.
Tulsa, Oklahoma 74136

918-392-4550